secwatch.observer — SEC 8-K summary
======================================

Issuer:     OptimizeRx Corp (OPRX)
CIK:        0001448431
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0001448431-25-000003
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OptimizeRx Q1 revenue up 11% to $21.9M; raises FY 2025 guidance
---------------------------------------------------------------

- Q1 revenue $21.9M (+11% YoY); gross profit $13.3M (+9% YoY).
- GAAP net loss ($2.2M) or ($0.12)/share; non-GAAP net income $1.5M ($0.08)/diluted share.
- Adjusted EBITDA $1.5M vs. ($0.3M) in prior-year Q1.
- FY 2025 guidance raised: revenue $101M–$106M, adjusted EBITDA $13M–$15M.
- Cash and investments $16.6M at March 31; net revenue retention 114%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1448431/000144843125000003/0001448431-25-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1448431/000144843125000003/oprx-20250512.htm
  HTML page:      https://secwatch.observer/filing/0001448431-25-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer